구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ZW25 (Zanidatamab) |
Overview Company | Jazz Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | HER2+/HR+ Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | inhibits HER2 signaling pathway |
MoA Biomarker | HER2-Positive |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.. Zanidatamab, a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, plus chemotherapy both with and without tislelizumab (anti-programmed death 1), showed encouraging efficacy and safety as first-line therapy in phase 2 studies involving patients with HER2-positive gastroesophageal ad… |
Toxicology CRS | Reported |
Clinical Safety signal | Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.. Zanidatamab, a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, plus chemotherapy both with and without tislelizumab (anti-programmed death 1), showed encouraging efficacy and safety as first-line therapy in phase 2 studies involving patients with HER2-positive gastroesophageal ad… |
Clinical Selected reported efficacy | ORR 33% |
Clinical Reported ORR | 34% |
Clinical Reported PFS | 5.49 |
Clinical Reported OS | 15.54 |
Clinical Result source | ClinicalTrials.gov NCT04466891 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04466891 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ZW25 (Zanidatamab) |
Overview Company | Jazz Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | HER2+/HR+ Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | inhibits HER2 signaling pathway |
MoA Biomarker | HER2-Positive |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.. Zanidatamab, a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, plus chemotherapy both with and without tislelizumab (anti-programmed death 1), showed encouraging efficacy and safety as first-line therapy in phase 2 studies involving patients with HER2-positive gastroesophageal ad… |
Toxicology CRS | Reported |
Clinical Safety signal | Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.. Zanidatamab, a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, plus chemotherapy both with and without tislelizumab (anti-programmed death 1), showed encouraging efficacy and safety as first-line therapy in phase 2 studies involving patients with HER2-positive gastroesophageal ad… |
Clinical Selected reported efficacy | ORR 33% |
Clinical Reported ORR | 34% |
Clinical Reported PFS | 5.49 |
Clinical Reported OS | 15.54 |
Clinical Result source | ClinicalTrials.gov NCT04466891 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04466891 |
추천 비교
추천 비교